Zobrazeno 1 - 10
of 138
pro vyhledávání: '"V, Avrillon"'
Autor:
J, Irani, S, Bart, V, Avrillon, B, Pogu, F X, Madec, S, Doizi, K, Bensalah, R, Mathieu, V, Phé, G, Pignot, C, Lebacle, D, Legeais
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 32(14)
The first part of this article deals with accreditation of the quality of the professional practice of urologists and medical teams working in public or private health care institutions. This is a voluntary national risk management process based on t
Autor:
M, Abdessater, P, Michel, F, Bardet, A, Kanbar, D, Legeais, P, Cabarrot, L, May-Michelangeli, V, Avrillon, G, Fournier, J-N, Cornu, B, Pogu, S, Bart
Publikováno v:
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
In 2018, the French High Authority of Health (HAS) included a "time-out" phase in the latest version of the checklist for the operating room in order to improve the safety of operated patients. The aim of this study is to evaluate the practice of Fre
Autor:
Yohann Loriot, Celine Mahier Ait Oukhatar, Benjamin Besse, S. Ortiz-Cuaran, Washington René Chumbi Flores, Jean-Yves Blay, Etienne Giroux Leprieur, Ludovic Lacroix, Mihaela Aldea, Claire Tissot, Clive Morris, Caroline Caramella, Julien Mazieres, Radj Gervais, Karen Howarth, Maurice Perol, Emma Green, Pierre Saintigny, Isabelle Monnet, C. Raynaud, Virginie Westeel, V. Avrillon, Etienne Brain, Jean-François Guichou, Camille Leonce, Maud Ngo-Camus, Anne Pradines, Frank de Kievit, Laura Mezquita, Sylvie Chabaud, Aurélie Swalduz, Cécile Jovelet, David Planchard, Luc Friboulet, N. Hoog-Labouret
Publikováno v:
Clinical Cancer Research
Purpose:The limited knowledge on the molecular profile of patients with BRAF-mutant non–small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these
Autor:
M. Abdessater, B. Pogu, F. Bardet, D. Legais, A. Kanbar, L. May-Michelangeli, V. Avrillon, G. Fournier, J. Cornu, P. Michel
Publikováno v:
Progrès en Urologie - FMC. 32:S34-S35
Autor:
Frank de Kievit, Laura Mezquita, Cécile Jovelet, David Planchard, Pierre Fournel, Christophe Massard, Luc Friboulet, Edouard Auclin, Emma Green, Solène Marteau, Pierre Saintigny, Caroline Caramella, Clive Morris, Jose Carlos Benitez, Maurice Perol, Benjamin Besse, Samuel Woodhouse, Aurélie Swalduz, K. Howarth, Etienne Rouleau, Claudio Nicotra, Julien Adam, Vincent Plagnol, Luc Odier, Claire Tissot, V. Avrillon, Ludovic Lacroix, Sandra Ortiz-Cuaran, Jordi Remon, Gonzalo Recondo
Publikováno v:
JCO Precision Oncology
JCO Precis Oncol
JCO Precis Oncol
PURPOSE Liquid biopsy specimen genomic profiling is integrated in non–small-cell lung cancer (NSCLC) guidelines; however, data on the clinical relevance for ALK /ROS1 alterations are scarce. We evaluated the clinical utility of a targeted amplicon-
Autor:
Xavier Quantin, Julien Mazieres, Samia Collot, P.J. Souquet, C. Tiffon, M. Jaffro, L. Favier, C. Mahier-Ait Oukhatar, Jacques Cadranel, Virginie Westeel, Jean Trédaniel, Claire Cropet, L. Montané, Fabrice Barlesi, Denis Moro-Sibilot, J. Le Treut, Etienne Brain, Gilbert Ferretti, J. Otto, Catherine Dubos-Arvis, Isabelle Monnet, J.-Y. Blay, V. Avrillon
Publikováno v:
Annals of Oncology. 31:289-294
Background BRAF mutations occurring in 1%–5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (I
Autor:
N. Girard, S. Galland-Girodet, V. Avrillon, B. Besse, M. Duruisseaux, J. Cadranel, J. Otto, A. Prevost, B. Roch, J. Bennouna, K. Bouledrak, M. Coudurier, T. Egenod, R. Lamy, C. Ricordel, D. Moro-Sibilot, L. Odier, J. Tillon-Strozyk, G. Zalcman, P. Missy, V. Westeel, S. Baldacci
Publikováno v:
ESMO open. 7(2)
ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) included small numbers of patients and real-world data are lacking. We inv
Publikováno v:
Progrès en Urologie - FMC. 32:S36
Publikováno v:
Revue des Maladies Respiratoires Actualités. 14:2S165-2S177
Autor:
T. Pierret, Maurice Pérol, Eric Fontaine, Denis Moro-Sibilot, A. Swalduz, Anne-Claire Toffart, V. Avrillon, J. Pinsolle, M. Giaj-Levra
Publikováno v:
Revue des Maladies Respiratoires. 37:349-351